Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novo Nordisk’s semaglutide cuts body weight in large-scale trial

pharmatimesFebruary 24, 2021

Tag: Novo Nordisk , Semaglutide , BMI , overweight , obesity

PharmaSources Customer Service